The atypical antipsychotics olanzapine and risperidone in the treatment of posttraumatic stress disorder: a meta-analysis of randomized, double-blind, placebo-controlled clinical trials
The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
Posttraumatic stress disorder (PTSD) is a prevalent and disabling mental illness. Small studies found atypical antipsychotics (AAs) to be beneficial in the treatment of patients with PTSD regardless of psychotic symptoms who are unresponsive to conventional pharmacological treatments such as serotonin selective reuptake inhibitors. This study reports the results of a meta-analysis of existing randomized, double-blind, placebo-controlled clinical trials (RCTs) of AAs as a monotherapy or augmentation therapy for the treatment of patients with PTSD. Seven RCTs were identified through extensive scans of databases, which included PubMed, MedLine, the National PTSD Center Pilots database, PsycINFO, Cochrane Central Register of Controlled Trials, and the Abstracts Library of the American Psychiatric Association with predefined inclusion criteria. Dichotomous and continuous measures were performed using a fixed effects model, heterogeneity was assessed, and subgroup analyses were done. Data from seven RCTs involving a total of 192 PTSD patients (102 randomized to AAs and 90 randomized to placebo) were analyzed. The results show that AAs may have a beneficial effect in the treatment of PTSD, as indicated by the changes from baseline in Clinician Administered PTSD Scale total scores [standardized mean difference (SMD)=-0.45, 95% confidence interval (CI) (-0.75, -0.14), P=0.004]. In addition, the overall SMD of the mean changes in the three Clinician Administered PTSD Scale subscores was statistically significant (P=0.007) between AAs and placebo groups, favoring AAs over placebo (SMD=-0.27, 95% CI=-0.47, -0.07). In particular, the symptom of 'intrusion' was mainly responsible for this significance. Clinical significance of the results, however, should be carefully interpreted and translated into clinical practice, given that the quality and availability of currently existing RCTs included in the analysis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The development of a Clinician-Administered PTSD Scale
Blake, D. D., Weathers, F. W., Nagy, L. M., Kaloupek, D. G., Gusman, F. D., Charney, D. S., & Keane, T. M. (1995) · Journal of Traumatic Stress · doi:10.1002/jts.2490080106 · Cited by 5,024 · cited 2×
“The primary efficacy measure was the mean change from baseline in the total scores on Clinician Administered PTSD Scale (CAPS) (Blake et al., 1995), which was the most frequently used assessment in the included RCTs (Stein et al., 2002; Hamner et al., 2003; Reich et al., 2004; Bartzokis et al.,…”
MethodResnick, H. S., Kilpatrick, D. G., Dansky, B. S., Saunders, B. E., & Best, C. L. (1993) · Journal of Consulting and Clinical Psychology · doi:10.1037/0022-006x.61.6.984 · Cited by 1,868 · cited 1×
“(Resnick et al., 1993; Kessler et al., 1995).”
Community Survey of Bipolar Disorder in Canada: Lifetime Prevalence and Illness Characteristics
Schaffer, A., Cairney, J., Cheung, A., Veldhuizen, S., & Levitt, A. (2006) · The Canadian Journal of Psychiatry · doi:10.1177/070674370605100104 · Cited by 143
Fineberg, N. A., Stein, D. J., Premkumar, P., Carey, P., Sivakumaran, T., Vythilingum, B., Seedat, S., Westenberg, H., & Denys, D. (2006) · International Clinical Psychopharmacology · doi:10.1097/01.yic.0000215083.57801.11 · Cited by 103 · cited 1×
“It allows critical comparisons between studies and comparator drugs as well as giving greater statistical power than individual trials (Fineberg et al., 2006).”
Background
Cited by
Katzman, M. A., Bleau, P., Blier, P., Chokka, P., Kjernisted, K., Van Ameringen, M., & the Canadian Anxiety Guidelines Initiative Group on behalf of the Anxiety Disorders Association of Canada/Association Canadienne des troubles anxieux and McGill University (2014) · BMC Psychiatry · doi:10.1186/1471-244x-14-s1-s1 · Cited by 1,090
“A meta-analysis of seven RCTs using atypical antipsychotics, either as monotherapy or adjunctively, concluded that these agents may be beneficial in the treatment of PTSD, particularly for the symptom of “intrusion” [1061].”
MethodMaes, M., Yirmyia, R., Noraberg, J., Brene, S., Hibbeln, J., Perini, G., Kubera, M., Bob, P., Lerer, B., & Maj, M. (2009) · Metabolic Brain Disease · doi:10.1007/s11011-008-9118-1 · Cited by 894
Watson, D., Levin‐Aspenson, H. F., Waszczuk, M. A., Conway, C. C., Dalgleish, T., Dretsch, M. N., Eaton, N. R., Forbes, M. K., Forbush, K. T., Hobbs, K. A., et al. (2022) · World Psychiatry · doi:10.1002/wps.20943 · Cited by 265
Berlim, M. T., & Van den Eynde, F. (2014) · The Canadian Journal of Psychiatry · doi:10.1177/070674371405900905 · Cited by 96
Bajor, L. A., Ticlea, A. N., & Osser, D. N. (2011) · Harvard Review of Psychiatry · doi:10.3109/10673229.2011.614483 · Cited by 76
Metadata
- Authors
- Pae, C.-U., Lim, H.-K., Peindl, K., Ajwani, N., Serretti, A., Patkar, A. A., & Lee, C.
- Venue
- International Clinical Psychopharmacology
- Published
- 2008-01
- Volume
- 23
- Issue
- 1
- Pages
- 1-8
- ISSN
- 0268-1315 (ISSN-L)
- OpenAlex
- W2016686222
- Cited by
- 140
- References
- 4
- FWCI
- 2.57
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The atypical antipsychotics olanzapine and risperidone in the treatment of posttraumatic stress disorder: a meta-analysis of randomized, double-blind, placebo-controlled clinical trials. https://app.cochat.ai/papers/10.1097/yic.0b013e32825ea324
- The paper
- Pae, C.-U., Lim, H.-K., Peindl, K., Ajwani, N., Serretti, A., Patkar, A. A., & Lee, C. (2008). The atypical antipsychotics olanzapine and risperidone in the treatment of posttraumatic stress disorder: a meta-analysis of randomized, double-blind, placebo-controlled clinical trials. International Clinical Psychopharmacology. https://doi.org/10.1097/yic.0b013e32825ea324
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.